Tubidy
    Kim N. Chi, MD, on what findings from the Phase III TITAN study mean for patients

    Kim N. Chi, MD, on what findings from the Phase III TITAN study mean for patients

    00:57 |
    Download MP3

    Related Videos

    Charles Rudin, MD, PhD, shares the take home message regarding Keynote-604 for lung cancer treatment 0:46

    Charles Rudin, MD, PhD, shares the take home message regarding Keynote-604 for lung cancer treatment

    William K. Oh, MD, considers the role of PARP inhibitors in mCRPC 2:37

    William K. Oh, MD, considers the role of PARP inhibitors in mCRPC

    Edward Kim, MD, describes how immunotherapy combinations will be used in the near future 1:36

    Edward Kim, MD, describes how immunotherapy combinations will be used in the near future

    Next-Gen Sequencing is Transforming Oncology Practices 4:27

    Next-Gen Sequencing is Transforming Oncology Practices

    Johnetta Blakely, MD, reflects on the progress and innovation of community oncologists 2:19

    Johnetta Blakely, MD, reflects on the progress and innovation of community oncologists

    Charles Loprinzi, MD, explains the role of palliative and supportive care in medical oncology 2:41

    Charles Loprinzi, MD, explains the role of palliative and supportive care in medical oncology

    Bo Gamble, compares and contrasts the definition of value and quality as it relates to cancer care 1:59

    Bo Gamble, compares and contrasts the definition of value and quality as it relates to cancer care

    Daniel M. Geynisman, MD, on how real-world analysis influences clinical decision-making 2:20

    Daniel M. Geynisman, MD, on how real-world analysis influences clinical decision-making

    Kim N. Chi, MD, on what findings from the Phase III TITAN study mean for patients 0:58

    Kim N. Chi, MD, on what findings from the Phase III TITAN study mean for patients

    Debra Patt, MD, PhD, MBA, on the promising investigations of CDK4/6 inhibitors 0:54

    Debra Patt, MD, PhD, MBA, on the promising investigations of CDK4/6 inhibitors

    Russell Gollard, MD, explains how IDNs effectively coordinate cancer care 1:44

    Russell Gollard, MD, explains how IDNs effectively coordinate cancer care

    Erin Stevens, MD, on why oncologists should be concerned about sexual health in their patients 0:18

    Erin Stevens, MD, on why oncologists should be concerned about sexual health in their patients

    Erika Hamilton, MD, on how CDK4/6 inhibitors transformed the management of metastatic breast cancer 1:12

    Erika Hamilton, MD, on how CDK4/6 inhibitors transformed the management of metastatic breast cancer

    The impact of clinical pathways on quality cancer care as explained by Bruce Gould, MD 0:37

    The impact of clinical pathways on quality cancer care as explained by Bruce Gould, MD

    Banu Arun, MD, regarding the optimal setting for PARP inhibitors in breast cancer treatment 0:22

    Banu Arun, MD, regarding the optimal setting for PARP inhibitors in breast cancer treatment

    Steven D'Amato, BSPharm, describes best practices and new programs being adopted to treat patients 1:29

    Steven D'Amato, BSPharm, describes best practices and new programs being adopted to treat patients

    Hani Babiker, MD, describes the setting of FDA approval on tumor treatment fields 0:19

    Hani Babiker, MD, describes the setting of FDA approval on tumor treatment fields

    Robert J. Brooks, MD, describes OneOncology's welcoming and impressive treatment resources 1:03

    Robert J. Brooks, MD, describes OneOncology's welcoming and impressive treatment resources

    Mary J. Fidler, MD, elaborates on what early clinical trials have told us about sotorasib 0:53

    Mary J. Fidler, MD, elaborates on what early clinical trials have told us about sotorasib

    Bert O’Neill, MD, on making immunotherapy more effective in mCRC 1:11

    Bert O’Neill, MD, on making immunotherapy more effective in mCRC